Compare ETD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETD | NMRA |
|---|---|---|
| Founded | 1932 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 554.0M |
| IPO Year | 1996 | 2023 |
| Metric | ETD | NMRA |
|---|---|---|
| Price | $20.46 | $1.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $27.00 | $7.50 |
| AVG Volume (30 Days) | 346.8K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $766,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $18.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.01 | $0.66 |
| 52 Week High | $31.41 | $3.65 |
| Indicator | ETD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 33.38 |
| Support Level | N/A | $1.53 |
| Resistance Level | $22.89 | $1.90 |
| Average True Range (ATR) | 0.56 | 0.23 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 14.01 | 4.57 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.